Commentary|Articles|January 16, 2026

AJMC® in the Press, January 16, 2026

Fact checked by: Maggie L. Shaw
Listen
0:00 / 0:00

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Articles published in Becker’s Hospital Review and TechTarget referenced a study published in the January 2026 issue of The American Journal of Managed Care® (AJMC®). The study, “Insights Into Patient Portal Engagement Leveraging Observational Electronic Health Data,” concluded that disparities in the use of the patient portal among adults with chronic conditions varied by patient characteristics, with lower usage noted in adults 65 years and older, non–English speakers, those with less than a college degree, and Black patients.

A study entitled, “Telemedicine Utilization and Preventive Services Among a Rural Population,” published in the January 2026 issue of AJMC, was referenced in an article published in Becker’s Hospital Review. The study found that residents of rural areas who used telemedicine were more likely to use preventive care between 2019 and 2023.

An article from Becker’s Hospital Review referenced a study published in the January 2026 issue of AJMC. The piece, “Subjective and Objective Impacts of Ambulatory AI Scribes,” found that physicians who had a majority of actual time savings in DocTime, or physician documentation time, were those who had higher relative baseline DocTime after introducing an AI scribe.

An article from McKnights Long-Term Care News referenced an article published on AJMC.com, the website of AJMC. The article, “Number of Medicare Beneficiaries With HIV Expected to Double in Next Decade,” covered the results of a study that found that costs for caring for those with HIV using Medicare would increase as the population of those with HIV 65 years and older would likewise grow.

A Q&A from AJMC entitled, “Amivantamab Plus Chemotherapy Delivers Durable Responses in RAS/BRAF Wild-Type mCRC: Filippo Pietrantonio, MD,” was referenced in an article from TechStock2. The Q&A focuses on updated data from the phase 1/2 OrigAMI-1 trial, which evaluates the efficacy of amivantamab in wild-type colorectal cancer. Early results show an objective response rate of 51%.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo